Schedule 13G ownership disclosure
TRAVERE THERAPEUTICS INC
Common Stock, par value $0.0001 per share · CUSIP: 89422G107
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Armistice Capital, LLC
Shares: 6,724,000.00 · Class: 7.52%
- Steven Boyd
Shares: 6,724,000.00 · Class: 7.52%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001172661-25-005160
- Form type
- SCHEDULE 13G/A
- Filer
- ARMISTICE CAPITAL, LLC
- CIK
- CIK 1601086
- Filed
- Nov 14, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership